Paradoxical psoriasis in pediatric tumor necrosis factor-α inhibitor therapy database
Authors:
- 23 July 2025
- journal article
- research article
- Published by Springer Nature in Pediatric Research
- Vol. 99 (3) , 958-963
Abstract
Background Paradoxical psoriasis (PP) is a class of adverse events associated with tumor necrosis factor α inhibitor (TNFi) that are realistically observed in the real world. We aim to quantify the signals of PP with TNFis in pediatric patients based on a pharmacovigilance study. Methods Data on pediatric PP cases linked to five TNFi drugs—etanercept, infliximab, adalimumab, certolizumab, and golimumab—were extracted from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q1 2023). PP event reports were assessed using ROR, PRR, BCPNN, MGPS, and logistic regression to conduct a disproportionality analysis and identify signal disparities. Results The FAERS database noted 563 pediatric PP cases, with 33.69% male and 66.31% female, representing 0.58% of all pediatric TNFi adverse event reports. The average age was 14 years. Among the five TNFis, four showed disproportionate reporting of PP: etanercept [ROR = 18.53], infliximab [ROR = 17.19], adalimumab [ROR = 10.23], and certolizumab [ROR = 3.95]. Conclusions The real-world FAERS pharmacovigilance data showed the safety signal for PP associated with TNFi in pediatric patients. Etanercept, infliximab, adalimumab, and certolizumab showed disproportionate reporting. Impact This study collected and analysed the data of paradoxical psoriasis (PP) associated with TNFis in pediatric patients from a worldwide pharmacovigilance database. Reports of PP adverse events accounted for 0.58% of the overall TNFi adverse event reports in pediatric patients. Among the five TNFis, we found disproportionate reporting of PP with etanercept, infliximab, adalimumab, and certolizumab in pediatric patients.Keywords
This publication has 21 references indexed in Scilit:
- Paradoxical Psoriasis: From its Many Faces to Possible Shared Therapeutic TargetsJournal of Investigative Dermatology, 2024
- Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α InhibitorsJAMA Dermatology, 2023
- Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune DiseasePediatric Drugs, 2021
- Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory DiseasesArthritis Care & Research, 2021
- A Critical Evaluation of Safety Signal Analysis Using Algorithmic Standardised MedDRA QueriesDrug Safety, 2018
- TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasisNature Communications, 2018
- Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year ExperienceAmerican Journal of Gastroenterology, 2015
- Quantitative signal detection using spontaneous ADR reportingPharmacoepidemiology and Drug Safety, 2009
- Distinct expression pattern of IFN- and TNF- in juvenile idiopathic arthritis synovial tissueRheumatology, 2006
- Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare eventsStatistics in Medicine, 2005